177906-46-6

Usage

Uses

Used in Organic Synthesis:
Cyclohexanol, 4-amino-1-methyl-, cis(9CI) is employed as a key intermediate in organic synthesis for the production of various chemical compounds. Its versatile structure allows for the creation of a range of molecules with different functional groups and properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Cyclohexanol, 4-amino-1-methyl-, cis(9CI) is used as a building block for the synthesis of new drug candidates. Its unique structure and functional groups make it a valuable component in the development of innovative pharmaceuticals with potential therapeutic applications.
Used in Drug Development:
Due to its potential applications in the development of new drugs and pharmaceuticals, Cyclohexanol, 4-amino-1-methyl-, cis(9CI) is utilized in drug discovery and development processes. Its unique chemical structure and properties may contribute to the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Research:
Cyclohexanol, 4-amino-1-methyl-, cis(9CI) is also used in chemical research to study the properties and reactions of aminocyclohexanol compounds. Understanding its reactivity and behavior in various chemical contexts can provide insights into the development of new synthetic methods and applications.

Upstream product

• 17429-02-6 4-hydroxy-4-methylcyclohexanone 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 66336-42-3 8-methyl-1,4-dioxa-spiro[4.5]decan-8-ol 

Downstream Products

• 25577-22-4 N-(4-methyl-cyclohex-3-enyl)-phthalimide 
• 1403864-55-0 tert-butyl 3-hydroxy-4-methylcyclohexylcarbamate 
• 291756-09-7 tert-butyl (4-methylcyclohex-3-en-1-yl)carbamate 
• 59477-37-1 4-methylcyclohex-3-enamine 

Relevant academic research and scientific papers

Application of Transaminases in a Disperse System for the Bioamination of Hydrophobic Substrates

The challenging bioamination of hydrophobic substrates has been attained through the employment of a disperse system consisting of a combination of a low polarity solvent (e. g. isooctane or methyl-tert-butylether), a non-ionic surfactant and a minimal amount of water. In these conditions, amine transaminases (ATA) were shown to efficiently carry out the reductive amination of variously substituted cyclohexanones, providing good conversions often coupled with a superior stereoselectivity if compared with the corresponding chemical reductive amination. An array of synthetically useful 4-substituted aminocyclohexanes was consequentially synthesized through biocatalysis, analyzed and stereochemically characterized. (Figure presented.).

N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl- cyclohexyl)-4

N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4- methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl- cyclohexyl)-4

Pyrimido?5,4-D!pyrimidines, medicaments comprising these compounds, their use and processes for their preparation

The present invention relates to pyrimido?5,4-d!pyrimidines of the general formula STR1 in which Ra to Rc are as defined herein, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibiting action on signal transduction mediated by tyrosine kinases, their use for the treatment of diseases, in particular tumor diseases.